FKL-137 是一种 GLUT1 和 PI3K/AKT 信号通路抑制剂,可结合 GLUT1,降低葡萄糖摄取与乳酸分泌,下调糖代谢相关蛋白,并下调 PI3K、p-PI3K、AKT、p-AKT 水平,破坏 PI3K/AKT-GLUT1 正反馈环路,同时通过上调 Bax、Cleaved-PARP 并下调 Bcl-2、PARP 诱导细胞凋亡 (apoptosis),从而抑制红白血病细胞增殖,可用于红白血病的研究。
FKL-137
产品编号: MS-T77884 分子式: C20H19F3N2O3 分子量: 392.37
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

FKL-137 是一种 GLUT1 和 PI3K/AKT 信号通路抑制剂,可结合 GLUT1,降低葡萄糖摄取与乳酸分泌,下调糖代谢相关蛋白,并下调 PI3K、p-PI3K、AKT、p-AKT 水平,破坏 PI3K/AKT-GLUT1 正反馈环路,同时通过上调 Bax、Cleaved-PARP 并下调 Bcl-2、PARP 诱导细胞凋亡 (apoptosis),从而抑制红白血病细胞增殖,可用于红白血病的研究。

生物实验数据

生物活性 FKL-137 is an inhibitor of GLUT1 and the PI3K/AKT signaling pathway that binds GLUT1, reduces glucose uptake and lactate secretion, downregulates glucose metabolism-related proteins, and downregulates PI3K, p-PI3K, AKT, and p-AKT levels, thereby disrupting the PI3K/AKT-GLUT1 positive feedback loop; it also induces apoptosis by upregulating Bax and Cleaved-PARP and downregulating Bcl-2 and PARP, ultimately inhibiting erythroleukemia cell proliferation, and can be used for research on erythroleukemia.
IC50 & Target

GLUT1

 

Akt

 

PI3K

 

体外研究
(In Vitro)

FKL-137 (0.001-10 μM;24-72 小时) 可强效抑制 HEL 和 K562 红白血病细胞的增殖;同时与 HepG2 肝癌细胞相比,其在正常 LX-2 肝细胞中表现出相对安全性。
FKL-137 (0.1-0.4 μM;48 小时) 可在 HEL 和 K562 红白血病细胞中诱导凋亡性细胞核变化。
FKL-137 (0.1-0.4 μM;48 小时) 可在 HEL 和 K562 红白血病细胞中诱导剂量依赖性凋亡,其中 K562 细胞在所有测试浓度下均检测到显著的凋亡细胞群,HEL 细胞则在 0.2-0.4 μM 浓度下检测到显著凋亡细胞群。
FKL-137 (0.1-0.4 μM;48 小时) 通过上调 Bax 和 Cleaved-PARP、下调 Bcl-2 和 PARP,调控 HEL 和 K562 红白血病细胞中凋亡相关蛋白的表达。
FKL-137 (0.1-0.4 μM;48 小时) 可下调 HEL 和 K562 红白血病细胞中糖代谢相关蛋白 HK2、PKM2 及 LDH 的表达。
FKL-137 (0.1-0.4 μM;48 小时) 以剂量依赖方式下调 HEL 和 K562 红白血病细胞中 PI3K、p-PI3K、AKT 及 p-AKT 的蛋白水平。
FKL-137 (0.1-0.4 μM;6-24 小时) 以剂量和时间依赖的方式抑制 HEL 和 K562 红白血病细胞的葡萄糖摄取和乳酸分泌,最早在 6 小时时即可观察到显著效应。
FKL-137 (0.001-10 μM;2 小时) 可提高 K562 红白血病细胞中 GLUT1 的热稳定性,且在 0.01-1 μM 浓度下不会改变 GLUT1 的总蛋白水平。
FKL-137 (0-0.6 μM;6 小时) 可抑制 K562 红白血病细胞中 GLUT1 介导的葡萄糖摄取,其 IC50 为 0.15 μM;且在高糖培养基中其抑制作用会减弱,证实其对 GLUT1 具有竞争性靶向作用。
FKL-137 (0.1-0.4 μM) 可在体外以剂量依赖的方式降低 HEL 红白血病细胞中 GLUT1 的表达。
FKL-137 (0.001-10 μM;48-72 小时) 在 72 小时时对 GLUT1 敲低的 K562 红白血病细胞表现出显著强于阴性对照细胞的、呈剂量和时间依赖性的抗增殖作用。
FKL-137 (0.1-0.4 μM;6-24 小时) 可进一步抑制 GLUT1 敲低的 K562 红白血病细胞的葡萄糖摄取与乳酸分泌,且在 12 小时内即可检测到显著效应。
FKL-137 (0.1-0.4 μM;48 小时) 可调控 GLUT1 敲低的 K562 红白血病细胞中代偿性上调的糖代谢相关蛋白 HK2 和 LDH 的表达。

Cell Viability Assay

Cell Line: human erythroleukemia HEL cells, human erythroleukemia K562 cells, human normal hepatic stellate LX-2 cells, human hepatoma HepG2 cells
Concentration: 0.001 μM; 0.01 μM; 0.1 μM; 1 μM; 10 μM
Incubation Time: 24 h, 48 h, 72 h
Result: Exerted significant, time- and dose-dependent inhibitory effects on HEL and K562 cell proliferation.
Achieved IC50 values of 0.6 μmol/L (24 h), 0.25 μmol/L (48 h), and 0.1 μmol/L (72 h) in HEL cells.
Achieved IC50 values of 0.8 μmol/L (24 h), 0.4 μmol/L (48 h), and 0.2 μmol/L (72 h) in K562 cells.
Exhibited hepatotoxicity safety index values of 1.65 (24 h), 1.66 (48 h), and 2.29 (72 h), indicating relative safety.

Apoptosis Analysis

Cell Line: human erythroleukemia HEL cells, human erythroleukemia K562 cells
Concentration: 0.1 μM; 0.2 μM; 0.4 μM
Incubation Time: 48 h
Result: Induced characteristic apoptotic morphological changes including nuclear condensation, fragmentation, and chromatin margination in both HEL and K562 cells.
Showed effects increasing with compound concentration.\nCaused a dose-dependent increase in apoptotic cell populations in both cell lines.
Increased early and late apoptosis rates significantly at 0.2 μM and 0.4 μM in HEL cells.
Increased early and late apoptosis rates significantly at all tested concentrations, with the highest effects at 0.4 μM in K562 cells.

Western Blot Analysis

Cell Line: human erythroleukemia HEL cells, human erythroleukemia K562 cells
Concentration: 0.1 μM; 0.2 μM; 0.4 μM
Incubation Time: 48 h
Result: Dose-dependently upregulated pro-apoptotic Bax and Cleaved-PARP protein expression in both HEL and K562 cells compared to DMSO controls.
Downregulated anti-apoptotic Bcl-2 and full-length PARP protein expression in both HEL and K562 cells compared to DMSO controls.\nDose-dependently downregulated the expression of glucose metabolism-related proteins HK2, PKM2, and LDH in both HEL and K562 cells compared to DMSO controls.\nDose-dependently downregulated the protein levels of PI3K, p-PI3K, AKT, and p-AKT in HEL and K562 cells.

Cell Viability Assay

Cell Line: GLUT1-knockdown (shGLUT1) human erythroleukemia K562 cells
Concentration: 0.001 μM; 0.01 μM; 0.1 μM; 1 μM; 10 μM
Incubation Time: 48 h, 72 h
Result: Exerted dose- and time-dependent anti-proliferative effects on GLUT1-knockdown K562 cells.
Showed significantly stronger inhibitory activity at 72 h compared to negative control (NC) cells.

Western Blot Analysis

Cell Line: GLUT1-knockdown (shGLUT1) human erythroleukemia K562 cells
Concentration: 0.1 μM; 0.2 μM; 0.4 μM
Incubation Time: 48 h
Result: Modulated the expression of compensatory upregulated glycolytic enzymes HK2 and LDH in GLUT1-knockdown K562 cells, where GLUT1 knockdown caused compensatory upregulation of HK2 and LDH.
体内研究
(In Vivo)

FKL-137 (1-10 mg/kg;腹腔注射;每 48 小时 1 次;共 7 次给药) 可剂量依赖性地升高 Fr-MuLV 诱导的红白血病小鼠的血细胞比容,减轻脾肿大并降低脏器系数,改善组织病理学损伤,降低脾脏葡萄糖和乳酸水平,同时下调代谢蛋白表达;其中 10 mg/kg 剂量的作用最为显著。

Animal Model: BALB/c (8-10 week old male and female; Fr-MuLV-induced erythroleukemia model established at 6 weeks of age)
Dosage: 1 mg/kg; 5 mg/kg; 10 mg/kg
Administration: i.p.; every 48 hours; 7 total doses
Result: Increased hematocrit to ~42% at 1 mg/kg, ~43% at 5 mg/kg, and ~55% at 10 mg/kg.
Reduced spleen weight to ~0.9 g at 1 mg/kg, ~0.4 g at 5 mg/kg, and ~0.2 g at 10 mg/kg.
Significantly reduced liver and spleen organ ratios across all doses; no significant changes to heart, lung, or kidney organ ratios were observed.
Significantly reduced pathological mitosis and tumor cell infiltration foci in spleen tissue across all doses compared to the model group.
Significantly reduced white blood cell infiltration in liver tissue across all doses compared to the model group; no significant histopathological changes were observed in heart, lung, or kidney tissues.
Reduced spleen glucose content to ~0.22 mmol/g and lactate content to ~0.28 mmol/g at 1 mg/kg; reduced spleen glucose content to ~0.12 mmol/g and lactate content to ~0.3 mmol/g at 5 mg/kg; reduced spleen glucose content to ~0.08 mmol/g and lactate content to ~0.3 mmol/g at 10 mg/kg.
Downregulated the expression of HK2 and LDH proteins in spleen tissue across all doses compared to the model group.

化学信息

分子量 392.37
分子式 C20H19F3N2O3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础